Obstructive Lung Disease Market Analysis

Global Obstructive Lung Disease Market Overview

Obstructive Lung Disease Market Size was valued at USD 23.84 Billion in 2023. The Global Obstructive Lung Disease industry is projected to grow from USD 24.32 Billion in 2024 to USD 52.16 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.12% during the forecast period (2024 - 2032).

Obstructive lung disease is a category of respiratory disease characterized by airway obstruction. Many obstructive diseases of the lung manifest due to the narrowing of bronchi which often cause excessive contraction of smooth muscles. 

The major types of obstructive lung disease include asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD). Increase in prevalence of COPD and asthma patients, rising geriatric population, increase in pipeline products, growing government and non-government initiatives for spreading awareness are the major factors driving the growth of the global obstructive lung diseases market.

Lupin Limited launched Vilfuro-G officially in India and released it as a fixed-dose triple combination therapy for chronic obstructive pulmonary disease (COPD) in November 2023. Drugs Controller General of India has approved the Dry Powder Inhaler (DPI). According to Lupin, Vilanteraol/Fluticasone Furoate/Glycopyrronium Bromide is the only once-daily dosing regimen with an inhaled fixed dose combination (FDC) available for the treatment of moderate to severe COPD over the long-term. This meets the needs of more than 37 million people with COPD in India who are one of its major causes of death and disability.

Theravance Biopharma, Inc. announced the results of its Phase 4 PIFR-2 study for YUPELRI® (revefenacin) on January 6, 2024. It is a long-acting muscarinic antagonist (LAMA) which is the first nebulized one approved in USA as a maintenance treatment of COPD once-daily. The aim was for PIFR-2 study to show greater improvement in lung function using YUPELRI delivered via standard jet nebulizer compared to Spiriva® delivered by dry powder inhaler (Spiriva® HandiHaler®) among adult patients with severe to very severe COPD having suboptimal peak inspiratory flow rate (PIFR).

Aditya Birla Health Insurance revealed ‘Activ One’ last month. Under such features, there are “100% Health Returns,” which allows policyholders to accrue rewards equal to their premium paid up to a maximum limit of 100 percent. Notably, it will also cover live-in relationships under this policy. These policies provide coverage even for chronic care benefits whereby they will be covering asthma, hypertension, diabetes mellitus with or without complications, chronic obstructive pulmonary disease (COPD), ischemic heart diseases, etc, from day one. The product features include 100% Health Returns, refill up to the base sum insured as many times as required in a policy year, Increasing the Sum Insured by six times in the sixth year of the policy term, no caps on room rent, ICU charges, etc. and coverage for all listed non-medical expenses related to hospitalization.

Tavulus®, developed by Glenmark Pharmaceuticals Limited, has been launched in Spain as a bioequivalent version of the Tiotropium Bromide dry powder inhaler (DPI) that is used to treat chronic obstructive pulmonary disease (COPD). COPD is a condition where lungs become inflamed over time, eventually resulting in damaged lung tissue, which narrows airways, hence making it difficult for one to cough. The number of people affected by COPD is estimated at 2.5 million in Spain. It’s anticipated that numerous patients will use this medicine in Spain. It keeps your airways open so that it becomes easier for airflow to get in and out of your lungs; it also acts against unanticipated short-term worsening of symptoms brought about by COPD.

As per the Global Burden of Disease study, it is estimated that chronic obstructive pulmonary disease caused 3.2 million deaths globally in 2015. Disease burden due to COPD was the highest in India, Nepal, Papua New Guinea, and Lesotho. COPD manifests itself as an occupational hazard in people working in agriculture, mining, plastics, and other industries.

Governments across each country have implemented regulations for the production, standardization, and utilization of COPD devices. These devices are divided into categories –Class-I, Class-II, Class-III, and Class-IV, depending upon the level of risk associated.

However, stringent government regulatory requirement for the approval of asthma and COPD drugs, side effects associated with the drug treatment, and patent expiry of drugs restrict the market growth.

Obstructive Lung Disease Market Segment Insights

The obstructive lung disease market is segmented on the basis of disease type, product type, drug class, route of administration and end-users.

Obstructive Lung Disease Type Insights

On the basis of disease type, the obstructive lung disease market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others. 

Obstructive Lung Disease Product Type Insights

On the basis of product type obstructive lung disease market is segmented into inhalers, and nebulizers and others. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs) and others. Moreover the nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers.

Obstructive Lung Disease Drug Class Insights

On the basis of drug class, the obstructive lung disease market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the Combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.

Obstructive Lung Disease Route of Administration Insights

On the basis of route of administration, obstructive lung disease market is segmented into oral, inhaler, intravenous, subcutaneous, and others.

Obstructive Lung Disease End-User Insights

On the basis of end-user, the obstructive lung disease market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Obstructive Lung Disease Market Top Key Players

The leading market players in the Asthma and COPD Drug focus to expand their business operations in the emerging countries. The companies operating in the market have consistently introduced innovative solutions to enhance their product portfolio. Product approval and clinical trial are observed as the two prominent growth strategies adopted by the key market players.

Some of key the players in the obstructive lung disease market are 

• GlaxoSmithKline (GSK) (U.K)


• Novartis AG (Switzerland)


• Merck & Co. Inc. (U.S)


• Abbott Laboratories (U.S)


• Boehringer Ingelheim (Germany)


• AstraZeneca (U.K)


• Roche Holding AG (Switzerland)


• Teva Pharmaceutical Industries (Israel)


• Vectura Group (U.K)


• Pfizer Inc. (U.S), 


• Mylan (U.S.)


• Aerovance Inc. (U.S.)


• Alkermes Inc. (U.S.)


• Almirall SA. (U.S.)


• Genentech Inc. (U.S.)


• Sepracor, Inc. (U.S.)


• Skyepharma plc (U.S.).

Obstructive Lung Disease Market Regional Analysis

The obstructive lung disease market consists of countries namely America, Europe, Asia Pacific, and the Middle East and Africa.

The Americas is projected to hold the largest share of the obstructive lung disease market due to presence of superior research and development base, strong regional economics, and greater emphasis on disease prevention and wellness by governments.

The European obstructive lung disease market is expected to witness rapid growth owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

Countries such as China, Japan, and India in Asia Pacific are also poised to be promising markets for obstructive lung disease in the near future. The healthcare expenditure in Asia increased due to an extension of state healthcare programs and the increasing affluence of the population. India is anticipated to witness an expansion in spending due to a government resolution to enhance healthcare services. Moreover, China and South Korea are s triving to develop their biotechnology sector for diagnosis purpose. China’s efforts to develop its biotech sector has shown good results in sectors such as vaccines and biological products and the same can be expected in the obstructive lung disease industry. However, low research and development (R&D) yields, high infrastructure cost, stringent regulatory framework are some of the restraints of the obstructive lung disease market.

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of healthcare infrastructure and growing emphasis on research and development in the healthcare sector.

Recent Development

November 2023: Lupin partners with Mark Cuban's company and COPD Foundation to improve availability and affordability of drugs to treat COPD in the US.

October 2023: AstraZeneca and Boehringer Ingelheim announce new clinical trials for their inhaled triple therapy for COPD.Novartis receives FDA approval for its new oral bronchodilator for COPD.

September 2023: GSK and Theravance Biopharmaceuticals announce new clinical trials for their inhaled dual bronchodilator for COPD.ResMed launches new COPD management platform.

August 2023: Philips Respironics launches new COPD therapy device.GlaxoSmithKline announces new partnership with COPD Foundation to improve care for people with COPD.

July 2023: Pfizer receives FDA approval for its new inhaled triple therapy for COPD.Teva announces new partnership with COPD Foundation to improve access to affordable COPD medications.

Intended Audience

• Obstructive Lung Disease Drug Suppliers


• Obstructive Lung Disease Drug Manufacturers


• Obstructive Lung Disease Device Suppliers


• Obstructive Lung Disease Device Manufacturers


• Research And Development (R&D) Companies


• Medical Research Laboratories


• Academic Medical Institutes and Universities